

Special Issue

COVID-19 and Kidney Transplantation: Clinical Outcomes, Management, and Challenges

Message from the Guest Editor

Several studies have reported that kidney transplant recipients (KTR) are at increased risk of severe COVID-19 infection. Furthermore, the efficacy of the vaccine is severely reduced in these patients. Therefore, individualized prevention strategies are essential for KTR. Adaptation of the vaccine scheme is recommended in these patients, including the use of an early third dose and of a fourth dose in vaccine responders. However, the net effect of each immunosuppressant on vaccine response may vary, and optimization of the immunosuppressive regimen to improve immunization is practicable. Minimization of immunosuppression and effects of conventional treatment of severe COVID infection are also crucial questions in patients with COVID-19 infection. Finally, a global and integrative approach to COVID-19 infection prevention is required.

This special issue aims to highlight current knowledge on COVID-19 in KTR. Different studies include personalized prevention, clinical outcomes, medical care, and future challenges. Indeed, this pandemic raises in an acute fashion the question of vaccine protocols and how to approach them in immunocompromised patients.

Guest Editor

Dr. Didier Ducloux

1. CHU Besançon, Department of Nephrology, Dialysis and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, 25000 Besançon, France
2. UMR RIGHT 1098, INSERM-EFS-UFC, 1 Bd Fleming, 25000 Besançon, France

Deadline for manuscript submissions

closed (20 July 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed




mdpi.com/si/109775

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).